A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with...

John Tse
Mar 1, 2021
1 min read

Updated: Apr 28, 2021

... temozolomide in patients with recurrent glioblastoma.

BACKGROUND: Preclinical data suggest some cannabinoids may exert antitumour effects against glioblastoma (GBM). Safety and preliminary efficacy of nabiximols oromucosal cannabinoid spray plus dose-intense temozolomide (DIT) was evaluated in patients with first recurrence of GBM.

https://www.nature.com/articles/s41416-021-01259-3.pdf

Source: British Journal of Cancer via nature.com

Recent Posts

See All

36Eight's CEO, John Tse, wins BC Pharmacy Association lifetime achievement award

Conversations that Matter: Cannabis as medicine

Association between county level cannabis dispensary counts and opioid related mortality rates...

Comments

bottom of page